Invion Limited (IVIXF) Prévision du cours des actions

Invion Ltd. is a clinical-stage life sciences company, which engages in the research and development of treatment for cancers, atherosclerosis, and infectious diseases. The company is headquartered in Melbourne, Victoria. The company went IPO on 2010-02-15. The firm is engaged in the research and development of Photosoft technology for the treatment of a range of cancers, atherosclerosis and infectious diseases. The firm is developing Photosoft technology as a Photodynamic Therapy (PDT). PDT uses non-toxic photosensitizers and light to selectively kill cancer cells and promote an anti-cancer immune response. PDT also offers an alternative treatment option aimed at achieving complete tumor regression and long-lasting remission. PDT has also demonstrated broad-spectrum activity across multiple infectious diseases, including bacteria, fungi and viruses. The company holds the Australia and New Zealand license rights and distribution rights to Hong Kong and the rest of Asia Pacific, excluding China, Macau, Taiwan and Japan, to the Photosoft technology for all cancer indications. The Company’s wholly owned subsidiary is Epitech Dermal Science Pty Ltd.